
# Operations Strategy at Galanz



By Melissa Chauvin






# Operations Strategy at Galanz



By Melissa Chauvin





# What is Millennium: Takeda Oncology Company?

### TheCaseSolutions.com

Millennium: Takeda Oncology Company is the leading American biopharmaceutical company located in Chambridge Massachusetts with 1,100 employees

Main focus is in oncology to improve the treatment of cancer around the world

"Deliver extraordinary medicines to patients with cancer worldwide through our science, innovation, and passion."

#### History

- Established in 1993 as a genomic company
- 1994 it had 20 alliances with leading pharmaceutical and biotechnology companies
- In May of 2005 Founder Mark Levin turned his company over to Dr.
   Deborah Dunsire
- In May of 2008 Millennium was acquired by Takeda Pharmaceutic Company

# History

- Established in 1993 as a genomic company
- 1994 it had 20 alliances with leading pharmaceutical and biotechnology companies
- In May of 2005 Founder Mark Levin turned his company over to Dr.
   Deborah Dunsire
- In May of 2008 Millennium was acquired by Takeda Pharmaceutical Company

# Mergers & Acquisitions

- 1999 merged with Leukosite-Campath
- 2000 merged with Cambridge Discovery Chemistry
- February 2002 merged with COR Therapeutics- Integrilin
- 2005 sold the rights to
  Integrilin to Schering-Plough
- 2003 Velcade was released number one drug

# Culture

- Millennium allows each employee to have a voice and make a difference
- Diversity
- Non-informal
- Non-bureaucratic
- Easy going
- Interactions with senior leaders
- Like to have fun

# Parent company

- Takeda Pharmaceutical Company Limited
- Established in 1781- almost as old as the United States
- Largest pharmaceutical company in Japan



Yasuchicka Hasegawa Chairman and CEO Takeda Pharmaceutical Company Limited

# Pipeline

Millennium Pharmaceuticals: Takeda Oncology Company has over 15 drugs in its pipeline

## Positions to apply for

#### **Associate Director- Scientific Intelligence:**

- Survey and provide scientific analysis of emerging and existing R&D technologies
- Assess trends and provide scientific landscapes across the oncology and immunology therapeutic areas